Usefulness of botulinum toxin in the treatment of chronic migraine
Article Sidebar
Publicación 6. Vol 7. Num 1 (Español (España))
HTML (Español (España))
EPUB (Español (España))
FLIP (Español (España))
Published:
Jan 5, 2023
Keywords:
Migraine Disorders, botulinum Toxins, Type A, therapeutics, headache
Main Article Content
Abstract
Introduction. Migraine is one of the leading causes of disability with a higher prevalence in women. The use of botulinum toxin has shown great efficacy in chronic treatment, reducing symptoms such as headache days. Objective. Describe the usefulness of botulinum toxin in the treatment of chronic migraine. Methodology. A non-experimental study of the bibliographic review type was developed on the usefulness of botulinum toxin in the treatment of chronic migraine in which scientific articles that were investigated in databases such as Pubmed and Scopus were used. The period of the articles included was the last 5 years. Results. it was possible to demonstrate the different benefits of onabotulinumtoxinA, adverse effects, and benefits compared to other first-line treatments. Conclusion. It is concluded that onabotulinumtoxinA has shown to be especially useful in the treatment of chronic migraine, decreasing the frequency of headaches days-months, reducing the severity of headaches, and increasing the quality of life.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
Armijos Ayala, A. D., & Chunchi Ayala, L. M. (2023). Usefulness of botulinum toxin in the treatment of chronic migraine. Ciencia Digital, 7(1), 97-112. https://doi.org/10.33262/cienciadigital.v7i1.2447
Section
Artículos
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Affatato, O., Moulin, T. C., Pisanu, C., Babasieva, V. S., Russo, M., Aydinlar, E. I., & Mwinyi, J. (2021). High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis. Journal of translational medicine, 19(1), 133. doi: https://doi.org/10.1186/s12967-021-02801-w
Aydinlar, E. I., Dikmen, P. Y., Kosak, S., & Kocaman, A. S. (2017). OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states, and sleep quality: a single-center prospective cohort study. The journal of headache and pain, 18(1), 23. doi: https://doi.org/10.1186/s10194-017-0723-4
Blumenfeld, A. M. (2018). Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. The journal of headache and pain, 19(1), 13. doi: https://doi.org/10.1186/s10194-018-0840-8
Blumenfeld, A. M., Patel, A. T., Turner, I. M., Mullin, K. B., Manack Adams, A., & Rothrock, J. F. (2020). Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine. Journal of primary care & community health, 11. doi: https://doi.org/10.1177/2150132720959936
Boudreau, G., Finkelstein, I., Graboski, C., Ong, M., Christie, S., Sommer, K., & Becker, W. J. (2022). OnabotulinumtoxinA improves quality of life in chronic migraine: The PREDICT study. Canadian Journal of Neurological Sciences, 49(4), 540-552. doi:10.1017/cjn.2021.153
Castrillo Sanz, A., Morollón Sánchez-Mateos, N., Simonet Hernández, C., Fernández Rodríguez, B., Cerdán Santacruz, D., Mendoza Rodríguez, A., & Duate García-Luis, J. (2018). Experience with botulinum toxin in chronic migraine. Neurología, 33(8), 499-504. doi: https://doi.org/10.1016/j.nrl.2016.09.004
Do, T. P., Hvedstrup, J., & Schytz, H. W. (2018). Botulinum toxin: A review of the mode of action in migraine. Acta neurologica Scandinavica, 137(5), 442-451. doi: https://doi.org/10.1111/ane.12906
Frampton, J. E., & Silberstein, S. (2018). OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. Drugs, 78(5), 589-600. doi: https://doi.org/10.1007/s40265-018-0894-6
González-Martínez, A., Planchuelo-Gómez, Á., Guerrero, Á. L., García-Azorín, D., Santos-Lasaosa, S., Navarro-Pérez, M. P., & Gago-Veiga, A. B. (2021). Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 42(12), 5087-5092. doi: https://doi.org/10.1007/s10072-021-05180-8
Gribbin, C. L., Dani, K. A., & Tyagi, A. (2021). Chronic Migraine: An Update on Diagnosis and Management. Neurology India, 69(1), S67-S75. doi: https://doi.org/10.4103/0028-3886.315972
Herd, C. P., Tomlinson, C. L., Rick, C., Scotton, W. J., Edwards, J., Ives, N. J., & Sinclair, A. J. (2019). Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ open, 9(7). doi: https://doi.org/10.1136/bmjopen-2018-027953
Kollewe, K., Gaul, C., Gendolla, A., & Sommer, K. (2021). Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. The journal of headache and pain, 22(1), 50. doi: https://doi.org/10.1186/s10194-021-01260-4
Martínez-Pías, E., Guerrero, Á. L., Sierra, Á., Trigo, J., & & García-Azorín, D. (2021). Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA. Toxins, 13(6), 432. doi: https://doi.org/10.3390/toxins13060432
Matharu, M., Halker, R., Pozo-Rosich, P., DeGryse, R., Manack Adams, A., & Aurora, S. K. (2017a). The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. The journal of headache and pain, 18(1), 78. doi: https://doi.org/10.1186/s10194-017-0784-4
Matharu, M., Pascual, J., Nilsson Remahl, I., Straube, A., Lum, A., Davar, G., & Johannes, C. (2017b). Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia: an international journal of headache, 37(14), 1384-1397. doi: https://doi.org/10.1177/0333102417724150
Pak, A. T., Üstün, İ., & Sengul, Y. (2021). Botulinum toxin type A wear-off phenomenon in chronic migraine patients: how long does the maximum efficiency last? Arquivos de neuro-psiquiatria, 79(10), 886–890. doi: https://doi.org/10.1590/0004-282X-ANP-2020-0542
Peters, G. L. (2019). Migraine overview and summary of current and emerging treatment options. The American journal of managed care, 25(2), S23-S24.
Ranoux, D., Martiné, G., Espagne-Dubreuilh, G., Amilhaud-Bordier, M., Caire, F., & Magy, L. (2017). OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study. The journal of headache and pain, 18(1), 75. doi: https://doi.org/10.1186/s10194-017-0781-7
Rothrock, J. F., Adams, A. M., Lipton, R. B., Silberstein, S. D., Jo, E., & Zhao, X. (2019). FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine. Headache, 59(10), 1700-1713. doi: https://doi.org/10.1111/head.13653
Ruscheweyh, R., Athwal, B., Gryglas-Dworak, A., Frattale, I., Latysheva, N., Ornello, R., & Stark, C. D. (2020). Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review with Analysis of Headache Diaries. Headache, 60(8), 1673–1682. doi: https://doi.org/10.1111/head.13925
Santoro, A., Copetti, M., Miscio, A. M., Leone, M. A., & Fontana, A. (2020). Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 41(7), 1809-1820. Doi: Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Shaterian, N., Shaterian, N., Ghanaatpisheh, A., Abbasi, F., Daniali, S., Jahromi, M. J., & Abdoli, A. (2022). Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review. Pain research & management. doi: https://doi.org/10.1155/2022/3284446
Shen, B., & Wang, L. (2020). Impact of the botulinum-A toxin on prevention of adult migraine disorders. Journal of integrative neuroscience, 19(1), 201-208. doi: https://doi.org/10.31083/j.jin.2020.01.1240
Stark, C., Stark, R., Limberg, N., Rodrigues, J., Cordato, D., Schwartz, R., & Jukic, R. (2019). Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study. The journal of headache and pain, 20(1), 81. doi: https://doi.org/10.1186/s10194-019-1030-z
Tassorelli, C., Aguggia, M., De Tommaso, M., Geppetti, P., Grazzi, L., Pini, L. A., & Cortelli, P. (2017). Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. The journal of headache and pain, 18(1), 66. doi: https://doi.org/10.1186/s10194-017-0773-7
Tassorelli, C., Tedeschi, G., Sarchielli, P., Pini, L. A., Grazzi, L., Geppetti, P., & Martelletti, P. (2018). Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert review of neurotherapeutics, 18(2), 167-176. doi: https://doi.org/10.1080/14737175.2018.1419867
Torres-Ferrus, M., Gallardo, V. J., Alpuente, A., & & Pozo-Rosich, P. (2020). influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. The journal of headache and pain, 21(1), 88. doi: https://doi.org/10.1186/s10194-020-01157-8
Vikelis, M., Argyriou, A. A., Dermitzakis, E. V., Spingos, K. C., Makris, N., & Kararizou, E. (2018). Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment. The journal of headache and pain, 19(1), 87. doi: https://doi.org/10.1186/s10194-018-0918-3
Winner, P. K., Kabbouche, M., Yonker, M., Wangsadipura, V., Lum, A., & Brin, M. F. (2020). A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents with Chronic Migraine. Headache, 60(3), 564-575. doi: https://doi.org/10.1111/head.13754
Wong, H. T., Khalil, M., & Ahmed, F. (2020). OnabotulinumtoxinA for chronic migraine during pregnancy: a real-world experience on 45 patients. The journal of headache and pain, 21(1), 129. doi: https://doi.org/10.1186/s10194-020-01196-1
Aydinlar, E. I., Dikmen, P. Y., Kosak, S., & Kocaman, A. S. (2017). OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states, and sleep quality: a single-center prospective cohort study. The journal of headache and pain, 18(1), 23. doi: https://doi.org/10.1186/s10194-017-0723-4
Blumenfeld, A. M. (2018). Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. The journal of headache and pain, 19(1), 13. doi: https://doi.org/10.1186/s10194-018-0840-8
Blumenfeld, A. M., Patel, A. T., Turner, I. M., Mullin, K. B., Manack Adams, A., & Rothrock, J. F. (2020). Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine. Journal of primary care & community health, 11. doi: https://doi.org/10.1177/2150132720959936
Boudreau, G., Finkelstein, I., Graboski, C., Ong, M., Christie, S., Sommer, K., & Becker, W. J. (2022). OnabotulinumtoxinA improves quality of life in chronic migraine: The PREDICT study. Canadian Journal of Neurological Sciences, 49(4), 540-552. doi:10.1017/cjn.2021.153
Castrillo Sanz, A., Morollón Sánchez-Mateos, N., Simonet Hernández, C., Fernández Rodríguez, B., Cerdán Santacruz, D., Mendoza Rodríguez, A., & Duate García-Luis, J. (2018). Experience with botulinum toxin in chronic migraine. Neurología, 33(8), 499-504. doi: https://doi.org/10.1016/j.nrl.2016.09.004
Do, T. P., Hvedstrup, J., & Schytz, H. W. (2018). Botulinum toxin: A review of the mode of action in migraine. Acta neurologica Scandinavica, 137(5), 442-451. doi: https://doi.org/10.1111/ane.12906
Frampton, J. E., & Silberstein, S. (2018). OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. Drugs, 78(5), 589-600. doi: https://doi.org/10.1007/s40265-018-0894-6
González-Martínez, A., Planchuelo-Gómez, Á., Guerrero, Á. L., García-Azorín, D., Santos-Lasaosa, S., Navarro-Pérez, M. P., & Gago-Veiga, A. B. (2021). Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 42(12), 5087-5092. doi: https://doi.org/10.1007/s10072-021-05180-8
Gribbin, C. L., Dani, K. A., & Tyagi, A. (2021). Chronic Migraine: An Update on Diagnosis and Management. Neurology India, 69(1), S67-S75. doi: https://doi.org/10.4103/0028-3886.315972
Herd, C. P., Tomlinson, C. L., Rick, C., Scotton, W. J., Edwards, J., Ives, N. J., & Sinclair, A. J. (2019). Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ open, 9(7). doi: https://doi.org/10.1136/bmjopen-2018-027953
Kollewe, K., Gaul, C., Gendolla, A., & Sommer, K. (2021). Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. The journal of headache and pain, 22(1), 50. doi: https://doi.org/10.1186/s10194-021-01260-4
Martínez-Pías, E., Guerrero, Á. L., Sierra, Á., Trigo, J., & & García-Azorín, D. (2021). Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA. Toxins, 13(6), 432. doi: https://doi.org/10.3390/toxins13060432
Matharu, M., Halker, R., Pozo-Rosich, P., DeGryse, R., Manack Adams, A., & Aurora, S. K. (2017a). The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. The journal of headache and pain, 18(1), 78. doi: https://doi.org/10.1186/s10194-017-0784-4
Matharu, M., Pascual, J., Nilsson Remahl, I., Straube, A., Lum, A., Davar, G., & Johannes, C. (2017b). Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia: an international journal of headache, 37(14), 1384-1397. doi: https://doi.org/10.1177/0333102417724150
Pak, A. T., Üstün, İ., & Sengul, Y. (2021). Botulinum toxin type A wear-off phenomenon in chronic migraine patients: how long does the maximum efficiency last? Arquivos de neuro-psiquiatria, 79(10), 886–890. doi: https://doi.org/10.1590/0004-282X-ANP-2020-0542
Peters, G. L. (2019). Migraine overview and summary of current and emerging treatment options. The American journal of managed care, 25(2), S23-S24.
Ranoux, D., Martiné, G., Espagne-Dubreuilh, G., Amilhaud-Bordier, M., Caire, F., & Magy, L. (2017). OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study. The journal of headache and pain, 18(1), 75. doi: https://doi.org/10.1186/s10194-017-0781-7
Rothrock, J. F., Adams, A. M., Lipton, R. B., Silberstein, S. D., Jo, E., & Zhao, X. (2019). FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine. Headache, 59(10), 1700-1713. doi: https://doi.org/10.1111/head.13653
Ruscheweyh, R., Athwal, B., Gryglas-Dworak, A., Frattale, I., Latysheva, N., Ornello, R., & Stark, C. D. (2020). Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review with Analysis of Headache Diaries. Headache, 60(8), 1673–1682. doi: https://doi.org/10.1111/head.13925
Santoro, A., Copetti, M., Miscio, A. M., Leone, M. A., & Fontana, A. (2020). Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 41(7), 1809-1820. Doi: Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Shaterian, N., Shaterian, N., Ghanaatpisheh, A., Abbasi, F., Daniali, S., Jahromi, M. J., & Abdoli, A. (2022). Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review. Pain research & management. doi: https://doi.org/10.1155/2022/3284446
Shen, B., & Wang, L. (2020). Impact of the botulinum-A toxin on prevention of adult migraine disorders. Journal of integrative neuroscience, 19(1), 201-208. doi: https://doi.org/10.31083/j.jin.2020.01.1240
Stark, C., Stark, R., Limberg, N., Rodrigues, J., Cordato, D., Schwartz, R., & Jukic, R. (2019). Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study. The journal of headache and pain, 20(1), 81. doi: https://doi.org/10.1186/s10194-019-1030-z
Tassorelli, C., Aguggia, M., De Tommaso, M., Geppetti, P., Grazzi, L., Pini, L. A., & Cortelli, P. (2017). Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. The journal of headache and pain, 18(1), 66. doi: https://doi.org/10.1186/s10194-017-0773-7
Tassorelli, C., Tedeschi, G., Sarchielli, P., Pini, L. A., Grazzi, L., Geppetti, P., & Martelletti, P. (2018). Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert review of neurotherapeutics, 18(2), 167-176. doi: https://doi.org/10.1080/14737175.2018.1419867
Torres-Ferrus, M., Gallardo, V. J., Alpuente, A., & & Pozo-Rosich, P. (2020). influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. The journal of headache and pain, 21(1), 88. doi: https://doi.org/10.1186/s10194-020-01157-8
Vikelis, M., Argyriou, A. A., Dermitzakis, E. V., Spingos, K. C., Makris, N., & Kararizou, E. (2018). Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment. The journal of headache and pain, 19(1), 87. doi: https://doi.org/10.1186/s10194-018-0918-3
Winner, P. K., Kabbouche, M., Yonker, M., Wangsadipura, V., Lum, A., & Brin, M. F. (2020). A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents with Chronic Migraine. Headache, 60(3), 564-575. doi: https://doi.org/10.1111/head.13754
Wong, H. T., Khalil, M., & Ahmed, F. (2020). OnabotulinumtoxinA for chronic migraine during pregnancy: a real-world experience on 45 patients. The journal of headache and pain, 21(1), 129. doi: https://doi.org/10.1186/s10194-020-01196-1